Table 1.
Characteristic | ADRs | ADRs/MDADsa | |
---|---|---|---|
N | % | ||
Seriousness | |||
Non-serious ADRs | 5331 | 96.8 | 1.45 |
Serious ADRs | 104 | 1.9 | 0.03 |
Not applicableb | 71 | 1.3 | 0.02 |
Total | 5506 | 100.0 | 1.50 |
Causality | |||
Certain | 615 | 11.2 | 0.17 |
Probable/likely | 393 | 7.1 | 0.11 |
Possible | 3711 | 67.4 | 1.01 |
Not assessable | 679 | 12.3 | 0.18 |
Not applicableb | 108 | 2.0 | 0.03 |
Total | 5506 | 100.0 | 1.50 |
Outcome | |||
Recovered/resolved | 3732 | 67.8 | 1.02 |
Recovering/resolving | 318 | 5.8 | 0.09 |
Recovered/resolved with sequelae | 13 | 0.2 | 0.00 |
Sequelae | 1 | 0.0 | 0.00 |
Not recovered/not resolved | 266 | 4.8 | 0.07 |
Fatal | 0 | 0.0 | 0.00 |
Unknown | 1097 | 19.9 | 0.30 |
Not assessable | 2 | 0.0 | 0.00 |
Not applicableb | 77 | 1.4 | 0.02 |
Total | 5506 | 100.0 | 1.50 |
Labellingc | |||
Yes | 3342 | 60.7 | 0.91 |
No | 1854 | 33.7 | 0.50 |
Equivalentd | 127 | 2.3 | 0.03 |
Not applicableb | 110 | 2.0 | 0.03 |
Unknown | 52 | 0.9 | 0.01 |
Not assessed | 20 | 0.4 | 0.01 |
No approval in | 1 | 0.0 | 0.00 |
Total | 5506 | 100.0 | 1.50 |
MDADs maximum daily administration doses sold, AMP anthroposophic medicinal product
a× 1 million
bNot applicable: incorrect use of the AMP, the ADR was reported in terms of lack of effect or similar, or the ADR was evaluated to be causally linked to another AMP that was concomitantly administered in that patient
cLabelling information on the ADR in the patient information leaflet
dEquivalent (similar) to the labelling of the ADR in the patient information leaflet